Peginterferon alfa-2b
- Generic Name
- Peginterferon alfa-2b
- Brand Names
- Pegintron, Sylatron
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 215647-85-1
- Unique Ingredient Identifier
- G8RGG88B68
- Background
Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting...
- Indication
Peginterferon alfa-2b is indicated for the treatment of HCV in combination with Ribavirin and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 . May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
...
- Associated Conditions
- Chronic Hepatitis C Virus (HCV) Infection, Melanoma
- Associated Therapies
- -
An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients
- Conditions
- Interventions
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Biocad
- Target Recruit Count
- 140
- Registration Number
- NCT02103439
- Locations
- 🇷🇺
State Institution of Nizhny Novgorod region "Regional Center for Prevention and Control of AIDS and other infectious diseases", Nizhny Novgorod, Russian Federation
🇷🇺State Budgetary Higher Vocational Education Institution Pacific State Medical University, Ministry of Health of the Russian Federation, Vladivostok, Russian Federation
🇷🇺State Public Healthcare Institution National Center for the Prevention and Control of AIDS and other infectious diseases of the Ministry of Health of the Republic of Tatarstan, Kazan, Republic Of Tatarstan, Russian Federation
Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2015-08-18
- Lead Sponsor
- Biocad
- Target Recruit Count
- 150
- Registration Number
- NCT01740089
- Locations
- 🇷🇺
Moscow State University of Medicine and Dentistry, Moscow, Russian Federation
HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin
- Conditions
- Interventions
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Anna Cruceta
- Target Recruit Count
- 128
- Registration Number
- NCT01718301
- Locations
- 🇪🇸
Hospital Clinic i Provincial de Barcelona, Barcelona, Spain
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
- Conditions
- Interventions
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 42
- Registration Number
- NCT01701063
Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection
- Conditions
- Interventions
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Theodor Bilharz Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT01653236
- Locations
- 🇪🇬
Theodor Bilharz Research Institute, Giza, Egypt
Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)
- Conditions
- Interventions
- First Posted Date
- 2012-05-02
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT01590225
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2017-04-28
- Target Recruit Count
- 31
- Registration Number
- NCT01496807
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Non-responder Genotype 2 Hepatitis C Infected Patients
- Conditions
- Interventions
- First Posted Date
- 2011-11-09
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT01468584
- Locations
- 🇯🇵
Toranomon Hospital, Minato-ku, Tokyo, Japan
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Relapser Genotype 2 Hepatitis C Infected Patients
- Conditions
- Interventions
- First Posted Date
- 2011-11-06
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 108
- Registration Number
- NCT01466192
- Locations
- 🇯🇵
Toranomon Hospital, Minato-ku, Tokyo, Japan
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2011-07-06
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Thomas Stauffer Larsen
- Target Recruit Count
- 202
- Registration Number
- NCT01387763
- Locations
- 🇩🇰
Dept of Hematology, Aalborg hospital, Aalborg, Denmark
🇩🇰Dept. of Hematology, Aarhus University Hospital, Aarhus, Denmark
🇩🇰Dept of Hematology, Herlev Hospital, Herlev, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.